INmune Bio Inc. to Host Third Quarter Conference Call
INmune Bio Inc. (NASDAQ: INMB), a pioneering clinical-stage company focused on inflammation and immunology, is set to hold a conference call to discuss the financial results of its third quarter. This call is scheduled for a Thursday, at 4:30 PM Eastern Time, where the management team will share important updates about the company's performance and future strategies.
Conference Call Details
For those interested in participating in the conference call, it is advisable to dial in about 5 to 10 minutes before the event starts. When you connect to the operator, be sure to request the INmune Bio Third Quarter Conference Call.
Date: Upcoming Thursday
Time: 4:30 PM Eastern Time
Participant Dial-in: 1-800-225-9448
International Dial-in: 1-203-518-9708
Conference ID: INMUNE
Accessing the Live Webcast
A live audio webcast of the conference call will be made available for those who prefer to join online. The link will allow participants to stream the call directly from their devices.
A transcript of the call will be available about 24 hours after the event. Additionally, there will be a replay available until November 13 by calling 1-844-512-2921 for US callers or 1-412-317-6671 for international participants. When calling, use the provided PIN number to access the replay.
Overview of INmune Bio Inc.
INmune Bio Inc. stands at the forefront of biopharmaceutical innovation, dedicated to developing solutions that engage and enhance the innate immune system. The company is pushing boundaries with its unique product platforms. One notable innovation is the Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform, designed to selectively neutralize soluble TNF, which plays a pivotal role in many diseases. Another key program is CORDStrom™, a platform that utilizes human umbilical cord-derived mesenchymal Stromal/Stem cells and has recently undergone successful clinical trials in treating recessive dystrophic epidermolysis bullosa.
Additionally, INKmune® represents a significant advancement aiming to prime natural killer cells, empowering them to combat minimal residual disease in cancer patients. Currently, this innovative approach is being tested in trials focused on metastatic castration-resistant prostate cancer.
Challenges and Opportunities Ahead
As with any clinical-stage company, INmune Bio Inc. faces various challenges as it navigates the complex landscape of drug development and regulatory approval. The nature of clinical trials can be unpredictable, and while the company is optimistic about its prospects, it remains vigilant regarding potential risks. These factors include the ability to produce adequate drug supplies for trials and securing necessary funding to sustain operations and facilitate ongoing research.
Investors and stakeholders are encouraged to stay informed as the company progresses through studies and trials, with results potentially paving the way for groundbreaking therapies in the future.
Contact Information
For any inquiries, you may reach out to the company's leadership:
David Moss
Chief Executive Officer
(858) 964-3720
info@inmunebio.com
Daniel Carlson
Head of Investor Relations
(415) 509-4590
dcarlson@inmunebio.com
Frequently Asked Questions
When is the INmune Bio Inc. conference call?
The conference call is scheduled for Thursday at 4:30 PM Eastern Time.
How can I participate in the conference call?
You can participate by dialing in 5 to 10 minutes before the call. The dial-in numbers are provided in the announcement.
Will there be a transcript available after the call?
Yes, a transcript will be available approximately 24 hours after the conclusion of the call.
What are INmune Bio's main product platforms?
INmune Bio has three main platforms: DN-TNF, CORDStrom™, and INKmune®. Each targets different aspects of immune response and disease treatment.
How can I contact INmune Bio for more information?
You can contact David Moss or Daniel Carlson using the provided email addresses or phone numbers for inquiries.
